| Patents and Inventions | |
| 1. | US Provisional Patent Application, Publication Number US20100152114 A1, “Antioxidant activity of GH-RH Antagonists” (Filed Nov 29, 2009; Inventors: Dr. Nektarios Barabutis and Dr. Andrew V. Schally) https://www.google.com/patents/US20100152114 |
| Book Chapters: Monogram | |
| 1. | Barabutis N (2012). Growth Hormone Releasing Hormone. Encyclopedia of Cancer, Article ID: 348857, Chapter ID: 7178 (2012 - Springer). Editor: Manfred Schwab, Chief Editor “Cancer Letters” |
| Reviews | |
| 2. | Barabutis N, Verin A, Catravas JD. The role of kinases in vascular permeability. Am J Physiol Lung Cell Mol Physiol. 2016 Nov 1;311(5):L832-L845. doi: 10.1152/ajplung.00233.2016. Epub 2016 Sep 23 |
| 1. | Barabutis N, Schally AV. Growth hormone-Releasing hormone. Extrapituitary effects in physiology and pathology. Cell Cycle. 2010 Oct 15;9(20):4110-6 |
| Editorials | |
| 2. | Barabutis N and Catravas JD. P53: The Wall Watcher. Med Surg Urol 2015, 4:4. |
| 1. | Barabutis N and Catravas JD. Anti-inflammatory activity of Hsp90 inhibitors in the vasculature. Medical & Surgical Urology, 2013 Jan; 2(1), 2013 doi: 10.4172/2168-9857.1000e104) |
| Original Research Papers: First Author | |
| 11. | Barabutis N, Dimitropoulou C, Gregory B and Catravas JD. P53 regulates vascular permeability by modulation of Rac1 and RhoA signaling. J Cell Mol Med. 2018 Mar;22(3):1792-1804. doi: 10.1111/jcmm.13460. Epub 2018 Jan 24 |
| 10. | Barabutis N, Khangoura V, Marik P and Catravas JD. Synergistic Role of Vitamin C and Cortisone against the LPS induced Acute Lung Injury. Chest. 2017 Jul 21. pii: S0012-3692(17)31276-X. doi: 10.1016/j.chest.2017.07.014 |
| 9. | Barabutis N, Dimitropoulou C, Birmpas C, Joshi A, Thangjam G, Catravas JD. p53 protects against LPS-induced lung endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol. 2015 Apr 15;308(8):L776-87. doi: 10.1152/ajplung.00334.2014 |
| 8. | Barabutis N, Handa V, Dimitropoulou C, Rafikov R, Snead CM, Kumar S, Joshi A, Thangjam G, Fulton DJ, Black SM, Patel V, Catravas JD. LPS induces pp60c-src-mediated tyrosine phosphorylation of Hsp90 in lung vascular endothelial cells and mouse lung. Am J Physiol Lung Cell Mol Physiol. 2013 Jun 15;304(12):L883-93. doi: 10.1152/ajplung.00419.2012 |
| 7. | Barabutis N, Siejka A, Schally AV. Growth Hormone Releasing Hormone induces the expression of nitric oxide. J Cell Mol Med, 2011 May;15(5):1148-55 |
| 6. | Barabutis N, Siejka A, Schally AV. Effects of Growth Hormone Releasing Hormone and its agonistic and antagonistic analogs in cancer and non cancerous cell lines. Int J Oncol, 2010 May;36(5):1285-1289 |
| 5. | Barabutis N, Siejka A, Schally AV, Block NL, Cai R, Varga JL. Activation of Mitogen Activated Protein Kinases by a Splice Variant of Growth Hormone Releasing Hormone Receptor. J Mol Endocrinol. 2010 Feb;44(2):127-34 |
| 4. | Barabutis N, Schally AV. Antioxidant activity of Growth Hormone-Releasing Hormone Antagonists in LNCaP human prostate cancer line. Proc Natl Acad Sci USA. 2008 Dec 23;105(51):20470-5 |
| 3. | Barabutis N, Schally AV. Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines. Br J Cancer, 2008 Jun 3;98(11):1790-6 |
| 2. | Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A, Kiaris H. Stimulation of proliferation
of MCF-7 breast cancer cells by a transfected splice variant of growth hormone – releasing
hormone receptor. Proc Natl Acad Sci USA, 2007 Mar 27;104(13):5575-9 |
| 1. | Barabutis N, Schally A.V. Growth hormone-Releasing hormone: Extrapituitary effects in physiology
and pathology. Cell Cycle. 2010 Oct 15;9(20):4110-6 “Cell Cycle” Impact Factor: 4.565 |
| Original Research Papers: Second Author | |
| 3. | Joshi AD, Barabutis N, Birmpas C, Dimitropoulou C, Thangjam G, Cherian-Shaw M, Dennison J, Catravas JD.
Histone deacetylase inhibitors prevent pulmonary endothelial hyperpermeability and
acute lung injury by regulating heat shock protein 90 function. Am J Physiol Lung Cell Mol Physiol. 2015 Dec 15;309(12):L1410-9. doi: 10.1152/ajplung.00180.2015 |
| 2. | Siejka A, Barabutis N, Schally AV. GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression
of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro.
Peptides. 2012 Sep;37(1):63-8 |
| 1. | Siejka A, Barabutis N, Schally AV. GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung
cancer cells. Cell Cycle. 2011 Nov 1;10(21):3714-8 |
| Original Research Papers: Last Author | |
| 4. | Siejka A, Schally AV, Barabutis N. The effect of LHRH antagonist Cetrorelix in crossover conditioned media from epithelial (BPH-1) and stromal (WPMY-1) prostate cells". Horm Metab Res. 2014 Jan;46(1):21-6. doi: 10.1055/s-0033-1349127 |
| 3. | Siejka A, Schally AV, Block NL, Barabutis N. Antagonists of Growth Hormone-Releasing Hormone inhibit the proliferation of human benign prostatic hyperplasia cells. Prostate. 2010 Jul 1;70(10):1087-93 |
| 2. | Siejka A, Schally AV, Barabutis N. Activation of Janus kinase/Signal transducer and activator of transcription 3 pathway by Growth Hormone Releasing Hormone. Cell Mol Life Sci, 2010 Mar;67(6):959-64 |
| 1. | Siejka A, Schally AV, Block NL, Barabutis N. Mechanisms of inhibition of human Benign Prostatic Hyperplasia in vitro by LHRH antagonist (Cetrorelix) BJU Int. 2010 Nov;106(9):1382-8 |
| Original Research Papers: Co-Author | |
| 6. | Kelley E. McQueeney, Joseph M. Salamoun, James C. Burnett, Nektarios Barabutis, Paula Pekic, Sophie Lewandowski, Danielle Llanza, John Cornelius, John D. Catravas, Charles N. Landen, Peter Wipf, John S. Lazo and Elizabeth R. Sharlow.. Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor. Oncotarget. 2017 Dec 30;9(9):8223-8240. doi: 10.18632/oncotarget.23787. eCollection 2018 Feb 2 |
| 5. | Thangjam GS, Birmpas C, Barabutis N, Gregory B, Clements M, Newton J, Fulton D, Catravas JD. Hsp90 inhibition suppresses NF-κB transcriptional activation via Sirt-2 in human endothelial cells.” Am J Physiol Lung Cell Mol Physiol. 2016 Apr 1:ajplung.00054.2016. doi: 10.1152/ajplung.00054.2016 |
| 4. | Hargrave B, Varghese F, Barabutis N, Catravas J, Zemlin C. Nanosecond Pulsed Platelet-Rich Plasma (nsPRP) Improves Mechanical and Electrical Cardiac Function Following Myocardial Reperfusion Injury”. Physiol Rep. 2016 Feb;4(4). pii: e12710. doi: 10.14814/phy2.12710 |
| 3. | Barman SA, Chen F, Su Y, Dimitropoulou C, Wang Y, Catravas JD, Han W, Orfi L, Szantai-Kis C, Keri G, Szabadkai I, Barabutis N, Rafikova O, Rafikov R, Black SM, Jonigk D, Giannis A, Asmis R, Stepp DW, Ramesh G, Fulton DJ. NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling. Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1704-15. doi: 10.1161/ATVBAHA.114.303848 |
| 2. | Thangjam GS, Dimitropoulou C, Joshi AD, Barabutis N, Shaw MC, Kovalenkov Y, Wallace CM, Fulton DJ, Patel V, Catravas JD. Novel mechanism of Attenuation of LPS Induced NFKB Activation by the Heat Shock Protein 90 Inhibitor, 17 N allylamino 17 demethoxygeldanamycin, in Human Lung Microvascular Endothelial Cells. Am J Respir Cell Mol Biol. 2014 May;50(5):942-52. doi: 10.1165/rcmb.2013-0214OC |
| 1. | Joshi, AD, Dimitropoulou, C., Thangjam, G, Snead C., Feldman, S., Barabutis, N., Fulton, D., Hou, Y., Kumar, S., Gorshkov, B., Verin, AD., Black, SM., and Catravas, JD. Heat Shock Protein Inhibitors Prevent LPS Induced Endothelial Barrier Dysfunction by Disrupting RhoA Signaling. Am J Respir Cell Mol Biol. 2014 Jan;50(1):170-9. doi: 10.1165/rcmb.2012-0496OC |